Lord Abbett & CO. LLC Invests $61.86 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Lord Abbett & CO. LLC purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,094,457 shares of the biotechnology company’s stock, valued at approximately $61,858,000. Lord Abbett & CO. LLC owned approximately 1.31% of ADMA Biologics at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. State Street Corp boosted its position in ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after buying an additional 4,945,063 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of ADMA Biologics by 26.8% during the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after acquiring an additional 1,442,799 shares during the period. Geode Capital Management LLC boosted its holdings in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after acquiring an additional 137,989 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares during the last quarter. Finally, Driehaus Capital Management LLC increased its position in ADMA Biologics by 17.3% in the second quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock worth $33,860,000 after purchasing an additional 447,743 shares during the period. Institutional investors own 75.68% of the company’s stock.

Analyst Ratings Changes

ADMA has been the topic of a number of research reports. HC Wainwright upped their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James lifted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

Insiders Place Their Bets

In other news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA opened at $18.59 on Friday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.39 billion, a P/E ratio of 66.39 and a beta of 0.70. The stock’s 50-day moving average price is $19.02 and its two-hundred day moving average price is $16.05. ADMA Biologics, Inc. has a 1 year low of $3.95 and a 1 year high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the prior year, the company earned $0.01 EPS. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.